Stockreport

Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases

Aptevo Therapeutics Inc.  (APVO) 
Last aptevo therapeutics inc. earnings: 8/9 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aptevotherapeutics.com/investor-overview
PDF Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs An [Read more]